Ratsional'noe lechenie revmatoidnogo artrita
- Авторлар: Murav'ev Y.V1
-
Мекемелер:
- Шығарылым: № 19 (2013)
- Беттер: 104-107
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/286464
- ID: 286464
Дәйексөз келтіру
Ашық рұқсат
Рұқсат берілді
Аннотация
The review presents the classification criteria for rheumatoid arthritis (RA), proposed by the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR). The main classes of drugs used in the treatment of RA, the approaches to the selection of treatment algorithm taking into account the presence or absence of contraindications to therapy, adverse events, clinical remission or low disease activity are described. The optimal scheme for the control of blood parameters during treatment with disease-modifying anti-rheumatic drug (DMARDs) is presented. It is concluded that methotrexate and DMARDs should be appointed immediately after the diagnosis of RA.
Негізгі сөздер
Толық мәтін
Әдебиет тізімі
- Насонов Е.Л., Каратеев Д.Е., Балабанова Р.М. Ревматоидный артрит // Ревматология. Национальное руководство / Под ред. Е.Л. Насонова, В.А. Насоновой. М., 2008. - С 290-331.
- Scott D.L.,Coulton B.L.,Symmons D.P.,Popert A.J. Long-termoutcome of treating rheumatoid arthritis: results after 20 years // Lancet. -1987. - Vol. 1(8542). - P. 1108-11.
- Pincus T., Callahan L.F., Sale W.G., et al. Severe functional decline,work disability, and increased mortality in 75 rheumatoid arthritispatients studied over 9 years// Arthritis Rheum. - 1984. - Vol. 27. - P. 864-72.
- van Nies J.A., Krabben A, Schoones J.W., at al. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review // Ann. Rheum. Dis. - 2013.- Apr 9. [Epub ahead of print].
- Bijlsma J.W., Weinblatt M.E. Optimal use of methotrexate: the advantages of tight control // Ann. Rheum. Dis. - 2007. - Vol. 66(11). -P. 1409-10.
- Aletaha D., Neogi T., Silman A.J., et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/ EuropeanLeague Against Rheumatism collaborative initiative// Ann. Rheum. Dis. - 2010. -Vol. 69. - P. 1580-88.
- Smolen J.S., Landewe R., Breedveld F.C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologicaldisease-modifying antirheumatic drugs//Ann. Rheum. Dis. - 2010. - Vol. 69. - P. 964-75.
- Ревматология: Клинические рекомендации / Под ред. акад. РАМН Е.Л. Насонова. 2-е изд., испр. и доп. М., 2010. - 752 с.
- Kumar P., Banik S. Pharmacotherapy options in rheumatoid arthritis// Clin. Med. Insights Arthritis Musculoskelet. Disord. - 2013. - Vol. 6. -P. 35-43.
- Trelle S., Reichenbach S., Wandel S., et al. Cardiovascular safety of non-steroidal antiinflammatory drugs: network meta-analysis // BMJ. - 2011. - Vol. 342. - P. 7086.
- Gotzsche P.C., Johansen H.K. Meta-analysis of short-term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis // BMJ. - 1998. -Vol. 316(7134). - P. 811-18.
Қосымша файлдар
